Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.5.1907

Evaluation of Several Screening Approaches for Detection of Cervical Lesions in Rural Shandong, China  

Zong, Li-Ju (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Zhang, You-Zhong (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Yang, Xing-sheng (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Jiang, Jie (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Cui, Bao-Xia (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Qiao, Yun-Bo (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Li, Li (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Jiang, Kan (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Zhang, Wen-Jing (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Kong, Bei-Hua (Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University)
Shen, Keng (Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.5, 2015 , pp. 1907-1912 More about this Journal
Abstract
Purpose: The study was designed to: (1) investigate the prevalence of high-risk human papillomavirus (HR-HPV) infection and cervical neoplasia; and (2) evaluate clinical performance of visual inspection with acetic acid/ Lugol's iodine (VIA /VILI), Pap smear, high-risk human papillomavirus (HR-HPV) DNA test for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and (3) explore appropriate screening approach in rural areas of Shandong Province. Materials and Methods: A total of 3,763 eligible women from Yiyuan County in Yimeng mountainous areas of rural Shandong, China, were enrolled and underwent Pap smear, HR-HPV DNA testing by Hybrid Capture 2 (HC2), and VIA /VILI tests. Women positive in any test were referred to colposcopy and biopsy as indicated. Results: The prevalence of HR-HPV infection among all enrolled women was 11.1% and that in healthy women was 9.9%. In total 33 cases of CIN1, 16 cases of CIN2, 6 cases of CIN3 but none of cervical cancer were detected and the crude prevalence of CIN2+ was 0.58%. For detecting CIN2+, the sensitivity of HR-HPV DNA testing, VIA/VILI, Pap smear was 90.9%, 77.3%, 81.8%, respectively. Pap smear had the best specificity of 98.2%, followed by HR-HPV DNA testing with specificity of 89.4%, VIA/VILI had the lowest specificity of 81.2%. Colposcopy referral rate of HR-HPV DNA testing, VIA/VILI, Pap smear was 11.1%, 18.5%, 2.3%, respectively. Conclusions: Our results suggest that HR-HPV DNA testing alone might be appropriate for primary cervical cancer screening in rural low-resource areas of Shandong Province, China.
Keywords
Cervical cancer screening; high-risk human papillomavirus DNA; rural areas; Shandong, China;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Arbyn M, Castellsague X, De Sanjose S, et al (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol, 22, 2675-86.   DOI
2 Bradley J, Coffey P, Arrossi S, et al (2006). Women's perspectives on cervical screening and treatment in developing countries: experiences with new technologies and service delivery strategies. Women health, 43, 103-21.   DOI
3 Chen C, Yang Z, Li Z, et al (2012). Accuracy of several cervical screening strategies for early detection of cervical cancer: a meta-analysis. Int J Gynecol Cancer, 22, 908-21.   DOI   ScienceOn
4 Clifford GM, Gallus S, Herrero R, et al (2005). Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 366, 991-8.   DOI
5 Dai M, Bao YP, Li N, et al (2006). Human papillomavirus infection in shanxi province, people's republic of China: a population-based study. Br J Cancer, 95, 96-101.   DOI
6 Denny L, Kuhn L, Pollack A, et al (2000). Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer, 89, 826-33.   DOI
7 Gravitt PE, Paul P, Katki HA, et al (2010). Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One, 5, 13711.   DOI   ScienceOn
8 Hesketh T, Lu L, Xing ZW (2005). The effect of China's onechild family policy after 25 years. N Engl J Med, 353, 1171-6.   DOI
9 Huang LJ (1982). Planned fertility of one-couple/one-child policy in the People's Republic of China. J Marriage Family, 44, 775-84.   DOI
10 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
11 Jeronimo J, Schiffman M (2006). Colposcopy at a crossroads. Am J Obstet Gynecol, 195, 349-53.   DOI
12 Kjaer SK, Breugelmans G, Munk C, et al (2008). Populationbased prevalence, type-and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer, 123, 1864-70.   DOI   ScienceOn
13 Li N, Shi JF, Franceschi S, et al (2009). Different cervical cancer screening approaches in a Chinese multicentre study. Br J Cancer, 100, 532-7.   DOI
14 Longatto-Filho A, Naud P, Derchain SF, et al (2012a). Performance characteristics of Pap test, VIA, VILI, HRHPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology. Virchows Archiv, 460, 577-85.   DOI
15 Massad LS, Einstein MH, Huh WK, et al (2013). 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstetrics Gynecol, 121, 829-46.   DOI   ScienceOn
16 Longatto-Filho A, Naud P, Derchain SF, et al (2012b). Performance characteristics of Pap test, VIA, VILI, HRHPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology. Virchows Arch, 460, 577-85.   DOI
17 Mahe C, Gaffikin L (2005). Screening test accuracy studies: how valid are our conclusions? application to visual inspection methods for cervical screening. Cancer Causes Control, 16, 657-66.   DOI
18 Maine D, Hurlburt S, Greeson D (2011). Cervical cancer prevention in the 21st century: cost is not the only issue. Am J Public Health, 101, 1549-55.   DOI
19 Moy LM, Zhao FH, Li LY, et al (2010). Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral. Int J Cancer, 127, 646-56.   DOI
20 Mukakalisa I, Bindler R, Allen C, et al (2014). Cervical cancer in developing countries: effective screening and preventive strategies with an application in Rwanda. Health Care Women Int, 35, 1065-80.   DOI
21 Muwonge R, Wesley RS, Nene BM, et al (2014). Evaluation of cytology and visual triage of human papillomavirus-positive women in cervical cancer prevention in India. Int J Cancer, 134, 2902-9.   DOI
22 Nahvijou A, Hadji M, Marnani AB, et al (2014). A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking. Asian Pac J Cancer Prev, 15, 8229-37.   DOI
23 Sankaranarayanan R, Nessa A, Esmy PO, et al (2012). Visual inspection methods for cervical cancer prevention. Best practice Res Clinical Obstetrics Gynaecol, 26, 221-32.   DOI
24 Pimple S, Shastri S (2014). Comparative evaluation of human papilloma virus-DNA test verses colposcopy as secondary cervical cancer screening test to triage screen positive women on primary screening by visual inspection with 5% Acetic acid. Indian J Cancer, 51, 117.   DOI
25 Qiao Y-l, Sellors JW, Eder PS, et al (2008). A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol, 9, 929-36.   DOI
26 Qiao Y (2010). Perspective of cervical cancer prevention and control in developing countries and areas. Chin J Cancer, 29, 1-3.   DOI
27 Sarian L, Derchain S, Naud P, et al (2005). Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America: this report refers to partial results from the LAMS (Latin AMerican Screening) study. J Med Screen, 12, 142-9.   DOI
28 Schiffman M, Wentzensen N, Wacholder S, et al (2011). Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer I, 103, 368-83.   DOI
29 Shi JF, Canfell K, Lew JB, et al (2012a). The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer, 130, 641-52.   DOI   ScienceOn
30 Shi JF, Chen JF, Canfell K, et al (2012b). Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Serv Res, 12, 123.   DOI
31 Wright TC, Jr., Kuhn L (2012). Alternative approaches to cervical cancer screening for developing countries. Best Pract Res Clin Obstet Gynaecol, 26, 197-208.   DOI
32 Solomon D, Davey D, Kurman R, et al (2002). The 2001 Bethesda System: terminology for reporting results of cervical cytology. Jama, 287, 2114-9.   DOI
33 Sun ZR, Ji YH, Zhou WQ, et al (2010). Characteristics of HPV prevalence among women in Liaoning province, China. Int J Gynaecol Obstet, 109, 105-9.   DOI
34 Wang XC, Sun LQ, Ma L, et al (2014). Prevalence and genotype distribution of human papillomavirus among women from Henan, China. Asian Pac J Cancer Prev, 15, 7333-6.   DOI
35 Wu RF, Dai M, Qiao YL, et al (2007). Human papillomavirus infection in women in Shenzhen City, people's republic of China, a population typical of recent Chinese urbanisation. Int J Cancer, 121, 1306-11.   DOI
36 Yuan X, Yang Y, Gu D, et al (2011). Prevalence of human papillomavirus infection among women with and without normal cervical histology in Shandong Province, China. Arch Gynecol Obstet, 283, 1385-9.   DOI